Dante Alexander Suffredini, MD| Critical Care Medicine | MedStar Health

Dante Alexander Suffredini, MD
Provider is directly employed by MedStar Health

Specialties: Critical Care Medicine

Languages: English

This doctor only sees patients in a hospital setting and does not schedule visits.

Conditions and procedures

Conditions I treat

  • Diabetic Ketoacidosis
  • Hypotension
  • Pulmonary Embolism
  • Respiratory Distress Syndrome
  • Respiratory Failure
  • Sepsis
  • Status Epilepticus
  • Third Degree Burn
  • Ventilator Dependent
Show All Show Less

Procedures I perform

  • Advanced Diagnostic Bronchoscopy
  • Arterial Line Placement
  • Central Line Insertion
  • Mechanical Ventilation
  • Paracentesis
  • Thoracentesis
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

110 Irving Street Northwest
Room 4B
Washington, DC, 20010

Get Directions

miles away


Board Certification: American Board of Internal Medicine, Pulmonary Disease

Board Certification: American Board of Internal Medicine, Internal Medicine

Board Certification: American Board of Internal Medicine, Critical Care Medicine

Fellowship Program: National Institute of Health (2017)

Residency Program: Johns Hopkins University School of Medicine (2016)

Residency Program: University of Maryland Medical System (2013)

Medical School: Boston University School of Medicine (2010)

News and publications

1) Suffredini DA. The Long Road to Normalcy Following Survival from COVID-10-Associated Acute Respiratory Distress Syndrome. Crit Care Med. 2021 Jun 1. doi: 10.1097/CCM.0000000000005150. 

2) Al-Abdouh A, Haddadin S, Matta A, Jabri A, Barbarawi M, Abusnina W, Radideh Q, Mhanna M, Suffredini DA, Michos ED. Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis. Crit Care Res Pract. 2021 May 15:5588483. doi: 10.1155/2021/5588483. 

3) Li Y, Cui X, Shiloach J, Wang J, Suffredini DA, Xu W, Liu W, Fitz Y, Sun J, Eichacker PQ. Hydrocortisone decreases lethality and inflammatory cytokine and nitric oxide production in rats challenged with B. anthracis cell wall peptidoglycan. Intensive Care Med Exp. 2020 Nov 18;8(1):67. 

4) Suffredini DA, Allison MG. A Rationale for Use of High Flow Nasal Cannula for Select Patients With Suspected or Confirmed Severe Acute Respiratory Syndrome Coronavirus-2 Infection. J Intensive Care Med. 2021 Jan;36(1):9-17. doi: 10.1177/0885066620956630. 

5) Suffredini DA, Lee JM, Peer CJ, Pratt D, Kleiner DE, Elinoff JM, Solomon MA. Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. BMC Pulm Med. 2018 Jul 11;18(1):112

6) Suffredini, DA, George JM and Masur H. Management of Antiretrovirals in Critically Ill Patients:  Great Progress but Potential Pitfalls. Crit Care Med. 2018 May;46(5):663-665

7) Suffredini DA, Cui X, Xu W, Li Y, Eichacker PQ. The Potential Pathogenic Contributions of Endothelial Barrier and Arterial Contractile Dysfunction to Shock Due to B. anthracis Lethal and Edema Toxins. Toxins (Basel). 2017 Dec 6;9(12).doi: 10.3390/toxins9120394

8) Suffredini DA, Li Y, Xu W, Mahtab M, Leppla M, Fitz Y, Cui X, Eichacker PQ. Hypotension and Lethality with B. anthracisEdema but not Lethal Toxin Challenge in Rats are Associated with Decreased Arterial Contractile Function and are Improved with Adefovir Treatment. Am J Physiol Heart Circ Physiol. 2017 Nov 1;313(5):H946-H958

9) Suffredini DA, Cui X, Jaswal D, Remy KE, Li Y, Sun J, Solomon SB, Fitz Y, Moayeri M, Leppla S, Eichacker PQ. Anthrax Immune Globulin Improves Hemodynamics and Survival During B. anthracis Toxin Induced Shock in Canines Receiving Titrated Fluid and Vasopressor SupportIntensive Care Med Exp. 2017 Oct 23;5(1):48.

10) Xu W, Ohanjandian L, Sun J, Cui X, Suffredini D, Li Y, Welsh J, Eichacker PQ. A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results. PLoS One. 2017 Aug 10;12(8):e0182879. doi: 10.1371/journal.pone.0182879

11) Suffredini DA, Xu W, Sun J, Barea-Mendoza J, Solomon SB, Brashears SL, Perlegas A, Kim-Shapiro DB, Klein HG, Natanson C, Cortés-Puch I. Parenteral irons versus transfused red blood cells for treatment of anemia during canine experimental bacterial pneumonia. Transfusion. 2017 Jun 27. doi: 10.1111/trf.14214

12) Li Y, Cui X, Xu W, Ohanjanian L, Sampath-Kumar H, Suffredini DA, Moayeri M, Leppla S, Fitz Y, Eichacker PQ. Nitric Oxide Production Contributes to Bacillus anthracis Edema Toxin Associated Arterial Hypotension and Lethality: Ex vivo and in vivo Studies in the Rat. Am J Physiol Heart Circ Physiol. 2016 311(3):H781-93

13) Suffredini DA, Sampath-Kumar H, Li Y, Ohanjanian L, Remy KE, Cui X, Eichacker, PQ. Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies. Toxins 2015, 7, 5417-5434

14) Bridges TM, Scheraga RG, Tulapurkar ME, Suffredini D, Liggett SB, Ramarathnam A, Potla R, Singh IS, Hasday JDPolymorphisms in human heat shock factor-1 and analysis of potential biological consequences. Cell Stress Chaperones. 2015 Jan;20(1):47-59

15) Wehman B, Griffith BP, Balwan A, Kon ZN, Suffredini DA, Evans C, Garcia JP, Iacono A. Long-term outcomes following alemtuzumab induction in lung transplantation. Heart Surg Forum. 2013 Oct;16(5):E252-6

16) Suffredini DA, Reed RM. How A Cigarette Can Twist The Heart. BMJ Case Rep. 2012 Jun 8;2012. pii: bcr2012006240

17) Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini DA, Berg M, Child R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006 Jul 15;66(14):7317-25

18) Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA and Childs R. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104:170-177